Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Recommendation of "Hold" by Brokerages

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $6.11.

A number of equities analysts recently weighed in on STRO shares. Piper Sandler raised shares of Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 price target on the stock in a report on Monday, June 16th. HC Wainwright reissued a "neutral" rating and issued a $2.00 price target on shares of Sutro Biopharma in a report on Tuesday, April 29th. Finally, Bank of America cut their price target on shares of Sutro Biopharma from $1.00 to $0.80 and set an "underperform" rating on the stock in a report on Monday, May 19th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd acquired a new position in shares of Sutro Biopharma in the fourth quarter valued at about $26,000. ProShare Advisors LLC increased its stake in Sutro Biopharma by 74.3% during the fourth quarter. ProShare Advisors LLC now owns 26,961 shares of the company's stock worth $50,000 after acquiring an additional 11,494 shares during the last quarter. Velan Capital Investment Management LP acquired a new stake in Sutro Biopharma during the fourth quarter worth $55,000. Invesco Ltd. grew its stake in shares of Sutro Biopharma by 54.2% in the fourth quarter. Invesco Ltd. now owns 38,749 shares of the company's stock valued at $71,000 after buying an additional 13,620 shares in the last quarter. Finally, Cerity Partners LLC acquired a new stake in shares of Sutro Biopharma in the first quarter valued at $25,000. 96.99% of the stock is owned by hedge funds and other institutional investors.

Sutro Biopharma Stock Performance

STRO traded up $0.00 during mid-day trading on Friday, reaching $0.76. 374,782 shares of the stock were exchanged, compared to its average volume of 1,123,298. The stock has a market capitalization of $64.50 million, a PE ratio of -0.26 and a beta of 1.64. The company has a 50 day moving average price of $0.84 and a two-hundred day moving average price of $1.18. Sutro Biopharma has a 1 year low of $0.52 and a 1 year high of $5.17.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.28). The company had revenue of $17.40 million during the quarter, compared to analysts' expectations of $11.61 million. Sutro Biopharma had a negative return on equity of 347.60% and a negative net margin of 373.66%. Sell-side analysts expect that Sutro Biopharma will post -2.92 EPS for the current fiscal year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.